Current and future challenges of antithrombotic agents and anticoagulants: Strategies for reversal of hemorrhagic complications.
D000818:Animals; D000906:Antibodies / Q000276:immunology / Q000627:therapeutic use; D000925:Anticoagulants / Q000008:administration & dosage* / Q000009:adverse effects / Q000627:therapeutic use; D015195:Drug Design; D005167:Factor VII / Q000627:therapeutic use; D015942:Factor VIIa; D005343:Fibrinolytic Agents / Q000008:administration & dosage* / Q000009:adverse effects / Q000627:therapeutic use; D000882:Haplorhini; D006470:Hemorrhage / Q000139:chemically induced / Q000517:prevention & control*; D006801:Humans; D019934:International Normalized Ratio; D023421:Models, Animal; D010455:Peptides / Q000627:therapeutic use; D019039:Platelet Glycoprotein GPIIb-IIIa Complex / Q000037:antagonists & inhibitors; D011726:Pyridinium Compounds / Q000627:therapeutic use; D018179:Receptors, Thrombin / Q000037:antagonists & inhibitors / Q000276:immunology; D011994:Recombinant Proteins / Q000627:therapeutic use
D000906:Antibodies; D000925:Anticoagulants; D005343:Fibrinolytic Agents; D010455:Peptides; D019039:Platelet Glycoprotein GPIIb-IIIa Complex; D011726:Pyridinium Compounds; D018179:Receptors, Thrombin; D011994:Recombinant Proteins; C021761:thienpydin; D005167:Factor VII; C103587:recombinant FVIIa; D015942:Factor VIIa